GlobeNewswire by notified

Boreo executes its capital efficiency focused strategy by exiting from SANY excavator business in Finland and Sweden

Share

BOREO PLC                        Investor news                       16 January 2023 at 14:00 EET

Boreo executes its capital efficiency focused strategy by exiting from SANY excavator business in Finland and Sweden

Boreo Plc and SANY Europe GmbH (“SANY”) have agreed to terminate their excavator dealership agreements in the Finnish and the Swedish markets. The existing dealership agreement for the Estonian market remains intact and HM Nordic Oü, a company part of Boreo’s Heavy Machines Business Area, continues to operate as the SANY dealer in the Estonian market. The decision of the termination follows SANY’s plans to reorganize its operations in the Nordic region and the updated strategy and strategic financial targets of Boreo published in September 2022.

“Our ambition is to own businesses with potential to deliver stable earnings growth with attractive returns on capital. While we see a great potential for growth for SANY products in the Finnish and the Swedish markets, the growth of the business requires significant investments and hence lacks the characteristic to deliver such returns on capital which we expect to be able to generate elsewhere. The initiative follows our resource allocation mindset and is well in line with our updated strategy and long-term strategic financial targets”, says Boreo CEO Kari Nerg.

“I would like to express my gratitude to our team for the good work done to establish the SANY brand to the markets. We continue with the sale, distribution and service activities in Finland and Sweden during a transition phase and ensure, in collaboration with SANY, a smooth roll-over to a new distribution structure. In Estonia, the ramp-up phase has been successful, and we have reached a meaningful market position in the country. Given the positive results and the close integration of the business with our Putzmeister operations we continue to develop the business in Estonia”, says Richard Karlsson, Head of Boreo’s Heavy Machines Business Area.

In the last 12 months ending Q3/2022, the SANY business in Finland and Sweden generated a total revenue of c. EUR 3,4 million and operational EBIT of c. EUR -0,4 million. At the end of FY22, the total net asset value attached to the Finnish and Swedish operations was c. EUR 3,0 million of which a write-off of c. EUR 0,3 million is expected and will be booked in the Q4/2022 result. The personnel engaged with the business will continue after a transition in other positions in Boreo’s Heavy Machines Business Area.

Vantaa, 16 January 2023

Boreo Plc
Kari Nerg
CEO

Distribution:
NASDAQ Helsinki Ltd
Principal media
www.boreo.com

Further information:

Kari Nerg
CEO
tel +358 44 341 8514

Aku Rumpunen
CFO
tel +358 40 556 3546

Boreo in brief:

Boreo is a company listed on Nasdaq Helsinki that creates value by owning, acquiring and developing small and medium sized companies in Northern Europe. Boreo's business operations are organized into three business areas: Electronics, Technical Trade and Heavy Machines.

Boreo’s main objective is to create shareholder value in the long-term. It aims to achieve this with an acquisition-driven strategy, creating optimal conditions for its businesses to increase sales and improve profitability, and by being a best-in-class home for its companies and personnel. ​

The Group's net sales in 2021 were EUR 122 million and it employs some 300 people in seven countries. The company’s headquarter is in Vantaa.


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Vereniging Aegon to participate in current share buyback program8.12.2023 20:00:00 CET | Press release

The Hague, December 8, 2023 - Aegon has entered into an agreement with its largest shareholder, Vereniging Aegon, to partially participate in Aegon’s current EUR 1.5 billion share buyback program. The repurchase of shares from Vereniging Aegon will commence as soon as Aegon has repurchased shares for an amount of EUR 750 million under the buyback program and is expected to run until the end of the share buyback program. Barring unforeseen circumstances, the share buyback is expected to be completed on or before June 30, 2024. As of December 7, Aegon has repurchased 149.8 million shares representing EUR 703.9 million. Aegon began its EUR 1.5 billion share buyback program on July 6, 2023 following the completion of the transaction to combine Aegon’s Dutch pension, life and non-life insurance, banking, and mortgage origination activities with a.s.r., that was announced on July 4, 2023. Vereniging Aegon will participate pro-rata in the share buyback program based on its combined common sha

Clean Motion AB skriver under projektavtal med EU8.12.2023 19:09:01 CET | Pressemelding

Elfordonstillverkaren Clean Motion AB har skrivit under ett projektavtal inom EU Horizon Europe programmet. Projektet GIANTS (Green Intelligent Affordable Nano Transport Solutions) har totalt 23 projektpartners och en total budget på 15,1 miljoner Euro varav 12 miljoner Euro är bidrag från EU. Clean Motion har den tredje största budgeten och kommer att tilldelas ett bidrag från EU på 1,3 miljoner Euro fördelat över projektperioden på 42 månader, med start i januari 2024. Clean Motion AB, en ledare inom utvecklingen av hållbara transportlösningar, är stolta över att meddela sitt deltagande i GIANTS-projektet, finansierat av EU inom ramen för Horizon Europe-programmet. Projektets totala budget uppgår till 15,1 miljoner euro där EU står för 12 miljoner euro. Clean Motions totala budget i projektet är 1,9 miljoner euro med EU-finansiering om 1,3 miljoner euro. Inom projektet som löper från januari 2024 och 42 månader framåt kommer vi att samarbeta med 22 andra partners, bland andra Renault

Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:50:33 CET | Press release

PRESS RELEASE Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software Wolters Kluwer CCH Tagetik AI-based financial planning solution empowers finance professionals to make faster and better-informed decisions. New York – Dec. 8, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that it has been recognized as a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. Earlier this month, Wolters Kluwer also received recognition as a Leader in the Gartner Magic Quadrant for Financial Close and Consolidation Software. CCH Tagetik Budgeting, Planning and Forecasting software is Wolters Kluwer’s AI-based, enterprise-wide planning solution, which helps global companies facilitate strategic, financial, and operational planning, including supply chain, workforce, and capital expenses. The solution, which supports customers across vertical industries, is particula

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment8.12.2023 17:50:00 CET | Press release

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programme Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgery) Kadcyla® (trastuzumab emtansine) compared to Herceptin® (trastuzumab): at the 7-year landmark OS rates were 89.07% and 84.37

Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation8.12.2023 17:45:00 CET | Press release

Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authorities Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.1 The inavolisib combination reduced the risk of disease worsening or death (progression-free survival; PFS) by 57% compared to palbociclib and fulvestrant alone (15.0 months vs 7.3 months;